AI breakthrough could catch returning cancer months earlier
NCT ID NCT07189520
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 29 times
Summary
This study tests whether a new AI system can find tiny amounts of cancer left behind after treatment (called minimal residual disease) earlier than current methods. It will involve 700 adults with rectal or esophageal cancer who are scheduled for surgery. The AI combines blood tests, genetic data, and scans to predict if cancer will return, aiming to improve accuracy by at least 20% over standard tools.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.